U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H35NO2.ClH
Molecular Weight 345.948
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DICYCLOMINE HYDROCHLORIDE

SMILES

Cl.CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2

InChI

InChIKey=GUBNMFJOJGDCEL-UHFFFAOYSA-N
InChI=1S/C19H35NO2.ClH/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17;/h17H,3-16H2,1-2H3;1H

HIDE SMILES / InChI
Dicyclomine is an anticholinergic tertiary amine used frequently by oral and parenteral route as an effective anti-spasmodic agent. Dicyclomine hydrochloride salt is approved under brand name bentyl for the treatment of functional bowel/irritable bowel syndrome. In addition is known, that dicyclomine is also used in morning and motion sickness, dysmenorrheal, intestinal hypermotility. It was shown, that Dicyclomine is a selective M1 and M3 muscarinic receptors antagonist, but os shown pharmacological activity via the M1 receptor.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
BENTYL

Approved Use

Dicyclomine hydrochloride oral solution is indicated for the treatment of functional bowel/irritable bowel syndrome.

Launch Date

1984
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
47.98 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICYCLOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
50.47 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICYCLOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
207.88 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICYCLOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
202.67 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICYCLOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.09 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICYCLOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.66 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICYCLOMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.8 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DICYCLOMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg single, oral
Highest recorded dose
unhealthy, 10 months
Health Status: unhealthy
Age Group: 10 months
Sex: unknown
Sources:
1500 mg single, oral
Highest recorded dose
unhealthy, adult
40 mg 4 times / day multiple, oral
Recommended
Dose: 40 mg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Other AEs: Dry mouth, Dizziness...
Other AEs:
Dry mouth (33%)
Dizziness (40%)
Vision blurred (27%)
Nausea (14%)
Somnolence (9%)
Asthenia (7%)
Nervousness (6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea 14%
40 mg 4 times / day multiple, oral
Recommended
Dose: 40 mg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Vision blurred 27%
40 mg 4 times / day multiple, oral
Recommended
Dose: 40 mg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Dry mouth 33%
40 mg 4 times / day multiple, oral
Recommended
Dose: 40 mg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Dizziness 40%
40 mg 4 times / day multiple, oral
Recommended
Dose: 40 mg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nervousness 6%
40 mg 4 times / day multiple, oral
Recommended
Dose: 40 mg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Asthenia 7%
40 mg 4 times / day multiple, oral
Recommended
Dose: 40 mg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Somnolence 9%
40 mg 4 times / day multiple, oral
Recommended
Dose: 40 mg, 4 times / day
Route: oral
Route: multiple
Dose: 40 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

PubMed

PubMed

TitleDatePubMed
A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.
2013-02
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011-07-14
A computer-automated touchscreen paired-associates learning (PAL) task for mice: impairments following administration of scopolamine or dicyclomine and improvements following donepezil.
2011-03
Opioid substitution therapy in manipur and nagaland, north-east india: operational research in action.
2010-12-01
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010-12
Survey on the use of psychotropic drugs by twelve military police units in the municipalities of Goiânia and Aparecida de Goiânia, state of Goiás, Brazil.
2010-12
Acupuncture reduces crying in infants with infantile colic: a randomised, controlled, blind clinical study.
2010-12
New approaches in the management of multiple sclerosis.
2010-11-24
Rhabdomyolysis associated with phentermine.
2010-11-15
Chiropractic diagnosis and management of non-musculoskeletal conditions in children and adolescents.
2010-06-02
Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions.
2010-04-07
Use of potentially inappropriate medicines in elderly: A prospective study in medicine out-patient department of a tertiary care teaching hospital.
2010-04
Antispasmodic and bronchodilator activities of Artemisia vulgaris are mediated through dual blockade of muscarinic receptors and calcium influx.
2009-12-10
Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment.
2009-12
Oxybutynin extended release for the management of overactive bladder: a clinical review.
2009-09-21
Rapid Hemodynamic Deterioration and Death due to Acute Severe Refractory Septic Shock.
2009-06
Development of functional gastrointestinal disorders after Giardia lamblia infection.
2009-04-21
[Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats].
2009-03
Self-medication for infants with colic in Lagos, Nigeria.
2009-02-04
Liver Injury with Features Mimicking Autoimmune Hepatitis following the Use of Black Cohosh.
2009
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
2008-11-13
Dicyclomine, an M1 muscarinic antagonist, reduces biomarker levels, but not neuronal degeneration, in fluid percussion brain injury.
2008-11
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
2008-11
Interaction between glutamatergic-NMDA and cholinergic-muscarinic systems in classical fear conditioning.
2008-09-30
Antagonism of muscarinic M1 receptors by dicyclomine inhibits the consolidation of morphine-associated contextual memory.
2008-07-01
Anticholinergic activity of 107 medications commonly used by older adults.
2008-07
Blockade of M1 muscarinic acetylcholine receptors modulates the methamphetamine-induced psychomotor stimulant effect.
2008-06-02
Topiramate induced acute angle closure glaucoma.
2008-03-28
Mechanisms underlying the antispasmodic and bronchodilatory properties of Terminalia bellerica fruit.
2008-03-28
Gastrointestinal, selective airways and urinary bladder relaxant effects of Hyoscyamus niger are mediated through dual blockade of muscarinic receptors and Ca2+ channels.
2008-02
Idiopathic (primary) achalasia.
2007-09-26
Improving the detection limits of antispasmodic drugs electrodes by using modified membrane sensors with inner solid contact.
2007-05-09
[Drug treatment of irritable bowel syndrome: an unmet need].
2007-03
American Gastroenterological Association institute medical position statement on the use of gastrointestinal medication in pregnancy.
2007-02
Role of muscarinic M1 receptors in inhibitory avoidance and contextual fear conditioning.
2006-09
Current gut-directed therapies for irritable bowel syndrome.
2006-07
Clinical inquiries. What is the best treatment for infants with colic?
2006-07
M1 receptors play a central role in modulating AD-like pathology in transgenic mice.
2006-03-02
Treatment of overactive bladder in the aging population: focus on darifenacin.
2006
The negative impact of litigation on women's health care.
2005-12
Interaction between M1-muscarinic and glutamatergic NMDA receptors on an inhibitory avoidance task.
2005-11-30
Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
2005-11
Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies.
2005-06-20
Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence.
2005-06
Infantile colic.
2005-06
Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.
1998-03
Aplastic anaemia associated with piroxicam.
1991-02
The effect of M1 muscarinic blockade on behavior and physiological responses following traumatic brain injury in the rat.
1990-03-12
Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells.
1989-04
Dicyclomine: worrying symptoms associated with its use in some small babies.
1984-03-24
Patents

Patents

Sample Use Guides

Adults-Oral. The only oral dose clearly shown to be effective is 160 mg per day (in 4 equally divided doses). Since this dose is associated with a significant incidence of side effects, it is prudent to begin with 80 mg per day (in 4 equally divided doses). Depending upon the patient’s response during the first week of therapy, the dose should be increased to 160 mg per day unless side effects limit dosage escalation. If efficacy is not achieved within 2 weeks or side effects require doses below 80 mg per day, the drug should be discontinued. Documented safety data are not available for doses above 80 mg daily for periods longer than 2 weeks. Adults-Intramuscular Injection. NOT FOR INTRAVENOUS USE. The intramuscular dosage form is to be used temporarily when the patient cannot take oral medication. Intramuscular injection is about twice as bioavailable as oral dosage forms; consequently, the recommended intramuscular dose is 80 mg daily (in 4 equally divided doses). Oral dicyclomine hydrochloride should be started as soon as possible and the intramuscular form should not be used for periods longer than 1 or 2 days.
Route of Administration: Other
Dicyclomine showed inhibitory action against several pathogenic bacteria. Dicyclomine inhibited most of the bacterial isolates tested at 25-100 microg/ml concentration, and a few were sensitive even at a lower concentration (10 microg/ml). Dicyclomine was found to be bacteriostatic in nature against Shigella dysenteriae 7, and bactericidal against S. aureus NCTC 6571, 8530, and 8531.
Name Type Language
DICYCLOVERINE HYDROCHLORIDE
EP   MART.   WHO-DD  
Preferred Name English
DICYCLOMINE HYDROCHLORIDE
JAN   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
DICYCLOVERINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
2-(Diethylamino)ethyl [bicyclohexyl]-1-carboxylate hydrochloride
Systematic Name English
DICYCLOMINE HYDROCHLORIDE [USP-RS]
Common Name English
BENTYL
Brand Name English
DIETHYLAMINOCARBETHOXY-BICYCLOHEXYL HYDROCHLORIDE
Systematic Name English
DICYCLOMINE HYDROCHLORIDE [MI]
Common Name English
DICYCLOMINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
DICYCLOMINE HYDROCHLORIDE [JAN]
Common Name English
NSC-404381
Code English
WYOVIN
Brand Name English
DICYCLOMINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
KOLANTYL HYDROCHLORIDE
Brand Name English
MERBENTYL
Brand Name English
BENTYLOL
Brand Name English
DICYCLOVERINE HYDROCHLORIDE [MART.]
Common Name English
(BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE
Common Name English
DICYCLOMINE HYDROCHLORIDE [VANDF]
Common Name English
Dicycloverine hydrochloride [WHO-DD]
Common Name English
1-CYCLOHEXYLHEXAHYDROBENZOIC ACID(BETA)-DIETHYLAMINOETHYL ESTER HYDROCHLORIDE
Systematic Name English
DICYCLOMINE HCL
Common Name English
Classification Tree Code System Code
CFR 21 CFR 310.201
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
NCI_THESAURUS C29704
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
NCI_THESAURUS C29698
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C28987
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
PUBCHEM
441344
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
SMS_ID
100000090526
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
DAILYMED
CQ903KQA31
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
EVMPD
SUB01676MIG
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
CAS
67-92-5
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
RS_ITEM_NUM
1191000
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
RXCUI
152021
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID0058778
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
MERCK INDEX
m4378
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL1123
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-671-1
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
DRUG BANK
DBSALT000698
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
CHEBI
4515
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
NSC
404381
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY
FDA UNII
CQ903KQA31
Created by admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
PRIMARY